CD79A and COVID-19: Studies with control groups showed no significant differences in the prevalence of aPLs in COVID-19 compared to other infections or autoimmune diseases [46,48,49,50], with the exception of IgG and IgM aCL (59% versus 35% and 32% versus 10%, respectively) [41], LA [51], and IgA aβ2GPI [52].